The curative effect and security of Neostigmine combined mannitol treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension or Abdominal Compartment Syndrome: A clinical control study

The curative effect and security of Neostigmine combined mannitol treatment of Acute Pancreatitis combined with Intra-abdominal Hypertension or Abdominal Compartment Syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006580

Enrollment

Unknown

Registered

2015-06-15

Start date

2015-07-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis combined with Intra-abdominal Hypertension or Abdominal Compartment Syndrome

Interventions

experimental group:Neostigmine combined mannitol

control group:conventional therapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for diagnosis and treatment of acute pancreatitis in 2013 Chinese guide AP; 2. According to the diagnostic standard of intra-abdominal hypertension and abdominal compartment syndrome of WSACS; 3. IAH II level or above, or to the diagnostic criteria of ACS; 4. IAH and ACS belong to the bloating, or at the same time, but by puncture drainage fluid after IAH and ACS treatment is invalid; 5. Age 18-70 one full year of life; 6. And signed the informed consent of patients.

Exclusion criteria

Exclusion criteria: 1. Mechanical intestinal obstruction patients; 2. Neostigmine taboo subjects; 3. Ming or mannitol allergic patients of neostigmine; 4. Refused to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
intra-abdominal pressure;	—

Countries

China

Contacts

Public ContactLv nong-hua

chenpengydcg@163.com+86 18702528509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026